Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Revenues (Tables)

Revenues (Tables)

3 Months Ended

Mar. 31, 2019

Schedule of revenues disaggregated by category

Revenues disaggregated by category were as follows (in thousands):


	Three Months Ended
	March 31,
	2019		2018
Product sales:
Gross product sales	$	9,916	$	—
Discounts and allowances		(1,862)		—
Product sales, net	$	8,054	$	—

Revenues from collaborations:
License revenues		4,499		—
Research and development services		71		—
Total revenues from collaborations		4,570		—
Total revenues	$	12,624	$	—

Schedule of revenues from product sales disaggregated by customers

The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our total revenues (as a percentage of total revenues):


	Three Months Ended
	March 31,
	2019		2018
Grifols		36%		—
ASD Healthcare and Oncology Supply		33%		—
McKesson Specialty Care Distribution Corporation		24%		—

Schedule of product revenue allowances and discounts

The following tables summarize activity in each of the product revenue allowance and reserve categories for the three months ended March 31, 2019 (in thousands):


	Chargebacks,		Government
	Discounts and		and Other
	Fees		Rebates		Returns		Total
Balance at January 1, 2019	$	622	$	843	$	170	$	1,635
Provision related to current period sales		855		706		99		1,660
Credit or payments made during the period		(735)		(323)		—		(1,058)
Balance at March 31, 2019	$	742	$	1,226	$	269	$	2,237